Aktiesnakken — Juni 2013
-
JB indleder med køb 140 ? er det franke?
-
-
jeg er kommet lidt sent ind i chatten, så troede det var der farlige frank kom ind i kampen
-
Voldsomt spread i Exiqon 7,9-9
-
Banken ser stort salgspotentiale i Arzerra, der for nyligt opnåede positive resultater i nye studier, ligesom også Daratumumab ser lovende ud ifølge Jyske Bank.
Fraværet af flere nyheder i den kommende tid sørger dog for, at Genmab - med den heftige kursstigning siden nytår - formentlig ikke har meget momentum at hente på kort sigt, vurderer banken.
-
For min skyld må den gerne lukke i 195 31/12
-
Skattefar slagter mine Genmab CFD'er hvis de stiger mere i år
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind